[{"id":"9604cfb1-e6e8-49f6-8502-880d232ccb42","acronym":"","url":"https://clinicaltrials.gov/study/NCT03113643","created_at":"2023-08-14T10:10:56.859Z","updated_at":"2024-07-02T16:34:27.434Z","phase":"Phase 1","brief_title":"SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","source_id_and_acronym":"NCT03113643","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/26/2017","start_date":" 06/26/2017","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-11"},{"id":"9436a8ff-5aa6-4f94-a70c-ecf2cecaa874","acronym":"NCI-2022-02215","url":"https://clinicaltrials.gov/study/NCT05285813","created_at":"2023-08-14T10:11:07.915Z","updated_at":"2024-07-02T16:34:58.922Z","phase":"Phase 2","brief_title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","source_id_and_acronym":"NCT05285813 - NCI-2022-02215","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vibecotamab (XmAb14045)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/06/2022","start_date":" 05/06/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"},{"id":"93a602fc-fef4-4ca8-ada5-f9aa24df7e29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720988","created_at":"2023-08-14T10:11:11.619Z","updated_at":"2025-02-25T15:45:00.769Z","phase":"Phase 1","brief_title":"Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05720988","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/03/2024","start_date":" 08/03/2024","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2026","study_completion_date":" 08/03/2026","last_update_posted":"2024-03-08"},{"id":"f9804601-1b5e-4001-940c-6e9301ecc5f3","acronym":"CP-MGD024-01","url":"https://clinicaltrials.gov/study/NCT05362773","created_at":"2022-05-05T15:53:53.535Z","updated_at":"2024-07-02T16:35:23.328Z","phase":"Phase 1","brief_title":"A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT05362773 - CP-MGD024-01","lead_sponsor":"MacroGenics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGD024"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-17"},{"id":"a498e32c-b2f0-40fb-8597-93fddf2b2869","acronym":"","url":"https://clinicaltrials.gov/study/NCT06034275","created_at":"2023-09-13T14:09:45.731Z","updated_at":"2024-07-02T16:35:23.633Z","phase":"Phase 1","brief_title":"Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies","source_id_and_acronym":"NCT06034275","lead_sponsor":"Vincerx Pharma, Inc.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIP943"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/13/2023","start_date":" 09/13/2023","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-12"},{"id":"50591c7e-2bb2-4a10-8880-29d3224dc148","acronym":"PEPN1812","url":"https://clinicaltrials.gov/study/NCT04158739","created_at":"2023-12-11T17:16:23.292Z","updated_at":"2024-07-02T16:35:26.619Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04158739 - PEPN1812","lead_sponsor":"Children's Oncology Group","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-12-11"},{"id":"7c0994a9-8277-4f13-b963-37bb1082d426","acronym":"CADENZA","url":"https://clinicaltrials.gov/study/NCT03386513","created_at":"2023-08-14T10:10:58.304Z","updated_at":"2024-07-02T16:35:41.144Z","phase":"Phase 1/2","brief_title":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","source_id_and_acronym":"NCT03386513 - CADENZA","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 179","initiation":"Initiation: 01/02/2018","start_date":" 01/02/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-03"},{"id":"23fe5699-b91c-473a-b6f8-99a276ffb074","acronym":"","url":"https://clinicaltrials.gov/study/NCT04272125","created_at":"2021-01-18T20:45:10.451Z","updated_at":"2024-07-02T16:35:50.369Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04272125","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"2f6c09fe-648a-43a4-b8de-c7035dd17c75","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265963","created_at":"2021-01-18T20:43:42.945Z","updated_at":"2024-07-02T16:35:50.304Z","phase":"Phase 1/2","brief_title":"CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04265963","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"ef9f33ba-d081-412c-af8d-bf768df5b986","acronym":"","url":"https://clinicaltrials.gov/study/NCT02715011","created_at":"2021-01-18T13:16:28.170Z","updated_at":"2024-07-02T16:36:25.083Z","phase":"Phase 1","brief_title":"Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT02715011","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JNJ-63709178"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 03/26/2021","primary_completion_date":" 03/26/2021","study_txt":" Completion: 03/26/2021","study_completion_date":" 03/26/2021","last_update_posted":"2021-08-31"},{"id":"fb7d666c-54c6-4059-a090-52088390aea8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02937103","created_at":"2021-01-18T14:25:20.027Z","updated_at":"2024-07-02T16:36:58.622Z","phase":"Phase 1/2","brief_title":"A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies","source_id_and_acronym":"NCT02937103","lead_sponsor":"Southwest Hospital, China","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"],"overall_status":"Unknown status","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2019-06-25"},{"id":"d7c95ee1-956c-45c4-a831-43623a7594bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556982","created_at":"2021-01-18T17:30:30.309Z","updated_at":"2024-07-02T16:37:10.067Z","phase":"Phase 1/2","brief_title":"CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）","source_id_and_acronym":"NCT03556982","lead_sponsor":"The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTL123"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2018-06-14"}]